Tiotropium

BreastfeedingPediatric
  • TRADE NAMES: Spiriva (Boehringer Ingelheim); Stiolto Respimat (Boehringer Ingelheim)
  • INDICATIONS: Bronchospasm (associated with COPD)
  • CLASS: Anticholinergic, Muscarinic antagonist
  • HALF-LIFE: 5–6 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Acetylcholinesterase inhibitors, Anticholinergics, Antihistamines, Botulinum Toxin (A & B), Cannabinoids, Conivaptan, Disopyramide, Domperidone, Haloperidol, Ketoconazole, Levodopa, MAO inhibitors, Memantine, Metoclopramide, Nefopam, Parasympathomimetics, PEG-Interferon, Phenothiazines, Potassium chloride, Pramlintide, Secretin, Sublingual nitrates, Tricyclic antidepressants

PREGNANCY CATEGORY: C

Stiolto Respimat is tiotropium and olodaterol.

Our database has 76 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
OCULAR
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tiotropium in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric